Using a pharmacogenomic algorithm to guide the treatment of depression

Autor: Joanna M. Biernacka, L L Eisterhold, Josiah D. Allen, J J Jordan, Maureen S. Drews, Joel G. Winner, David A. Mrazek, R S Nesheim, Daniel K. Hall-Flavin, Karen Snyder
Rok vydání: 2012
Předmět:
Adult
Male
medicine.medical_specialty
Genotyping Techniques
Pharmacogenomic Testing
Pilot Projects
Ambulatory Care Facilities
Cohort Studies
Cellular and Molecular Neuroscience
Patient satisfaction
Cytochrome P-450 Enzyme System
Internal medicine
genomics
Medicine
Humans
Receptor
Serotonin
5-HT2A
Dosing
Prospective Studies
Prospective cohort study
Psychiatry
Biological Psychiatry
Depression (differential diagnoses)
Aged
Psychiatric Status Rating Scales
Serotonin Plasma Membrane Transport Proteins
pharmacogenomics
Depressive Disorder
Major
business.industry
psychiatric treatment
Hamilton Rating Scale for Depression
personalized medicine
Middle Aged
Antidepressive Agents
Psychiatry and Mental health
Treatment Outcome
Pharmacogenetics
Cohort
depression
Female
Original Article
business
Algorithms
Cohort study
Zdroj: Translational Psychiatry
ISSN: 2158-3188
Popis: The objective of this study was to evaluate the potential benefit of utilizing a pharmacogenomic testing report to guide the selection and dosing of psychotropic medications in an outpatient psychiatric practice. The non-randomized, open label, prospective cohort study was conducted from September 2009 to July 2010. In the first cohort, depressed patients were treated without the benefit of pharmacogenomic testing (the unguided group). A DNA sample was obtained from patients in the unguided group, but the results were not shared with either the physicians or patients until the end of the 8-week study period. In the second cohort (the guided group), testing results were provided at the beginning of the 8-week treatment period. Depression ratings were collected at baseline and after 2 weeks, 4 weeks and 8 weeks of treatment using the Quick Inventory of Depressive Symptomatology, Clinician Rated (QIDS-C16) and the 17-item Hamilton Rating Scale for Depression (HAM-D17). Clinician and patient satisfaction was also assessed. The reduction in depressive symptoms achieved within the guided treatment group was greater than the reduction of depressive symptoms in the unguided treatment group using either the QIDS-C16 (P=0.002) or HAM-D17 (P=0.04). We concluded that a rapidly available pharmacogenomic interpretive report provided clinical guidance that was associated with improved clinical outcomes for depressed patients treated in an outpatient psychiatric clinic setting.
Databáze: OpenAIRE
Externí odkaz: